Cancer killer cell group has two shots at success
The Irish Times – View full story
Entries by nacnkcell
ONK closes $21.5 million series A for cord blood-derived NK cell therapy
BioWorld – View full story (behind paywall)
Galway cancer killer cell group ONK raises €19 million
The Irish Times – View full story
ONK Therapeutics Announces $21.5M Series A Financing to Advance Pipeline of Next-Generation Optimally Engineered Off-the-Shelf NK Cell Therapies
$21.5 million Series A round led by current investors Acorn Bioventures and ALSHC, joined by new investor Cormorant Asset Management Financing will drive multiple pre-clinical programs through IND-enabling studies and the continued progression of a GMP manufacturing capability Galway, Ireland and San Diego, USA, 06 January 2022 – ONK Therapeutics, an innovative NK cell therapy […]
Killer cells: delivering a knockout blow to cancers
The Irish Times – View full story
USPTO Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies
The US Patent and Trademark Office (USPTO) has granted ONK Therapeutics’ patent for CISH knockout (KO) in Natural Killer (NK) cells based on the earliest scientific discoveries The patent, under exclusive global license from WEHI, gives ONK key IP for CISH KO in human NK cells for their use in cancer therapies, irrespective of cell […]
ONK Therapeutics’ CSO Prof. M O’Dwyer and his Academic Group Present New Data Showing the Benefit of Knocking Out the Inhibitory Receptor CD96 on Human NK Cells in the Context of Multiple Myeloma at EHA 2021
The checkpoint inhibitor CD96 was shown conclusively to be an inhibitory receptor on human NK cells in the presence of multiple myeloma (MM) cells expressing CD155 CD96 knock out (KO) using CRISPR/Cas9 gene editing enhanced both NK cell cytotoxicity and cytokine release Efficient engineering of NK cells to genetically eliminate inhibitory receptor expression has the potential […]
